Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours

European Urology

Volumn 60, Issue 2, 2011, Pages 350-357

  Fleischmann, Achim ^a   Rotzer, Diana ^a   Seiler, Roland ^a   Studer, Urs E ^a   Thalmann, George N ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Bladder cancer; FISH; Her2; Metastases; Survival; Tissue microarray

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BLADDER CANCER; CYSTECTOMY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; UROTHELIAL BLADDER CANCER;

ADULT; AGED; AGED, 80 AND OVER; CYSTECTOMY; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; SWITZERLAND; TIME FACTORS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 79959556990     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.05.035     Document Type: Article

References (22)

1. L. Harris, H. Fritsche, and R. Mennel American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer J Clin Oncol 25 2007 5287 5312 (Pubitemid 350232263)
2. A.C. Wolff, M.E. Hammond, and J.N. Schwartz American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 2007 118 145 (Pubitemid 350003059)
3. C.A. Hudis Trastuzumab - mechanism of action and use in clinical practice N Engl J Med 357 2007 39 51 (Pubitemid 47026733)
4. S. Kruger, I. Lange, I. Kausch, and A.C. Feller Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder - a multitissue array study with prognostic implications Anticancer Res 25 2005 263 271 (Pubitemid 40470119)
5. M. Lae, J. Couturier, S. Oudard, F. Radvanyi, P. Beuzeboc, and A. Vieillefond Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients Ann Oncol 21 2009 815 819
6. Z. Latif, A.D. Watters, I. Dunn, K. Grigor, M.A. Underwood, and J.M. Bartlett HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer 40 2004 56 63 (Pubitemid 37542318)
7. H. Matsubara, Y. Yamada, and K. Naruse Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization Oncol Rep 19 2008 57 63 (Pubitemid 351176131)
8. R. Simon, R. Atefy, and U. Wagner HER-2 and TOP2A coamplification in urinary bladder cancer Int J Cancer 107 2003 764 772 (Pubitemid 37339730)
9. N.H. Stoecklein, and C.A. Klein Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis Int J Cancer 126 2010 589 598
10. A. Fleischmann, G.N. Thalmann, R. Markwalder, and U.E. Studer Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor J Clin Oncol 23 2005 2358 2365 (Pubitemid 46218729)
11. J.P. Stein, G. Lieskovsky, and R. Cote Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients J Clin Oncol 19 2001 666 675 (Pubitemid 32120143)
12. J.A. Garcia, and R. Dreicer Systemic chemotherapy for advanced bladder cancer: update and controversies J Clin Oncol 24 2006 5545 5551 (Pubitemid 46631335)
13. A.P. Marin, E.E. Arranz, A.R. Sanchez, P.Z. Aunon, and M.G. Baron Role of anti-Her-2 therapy in bladder carcinoma J Cancer Res Clin Oncol 136 2010 1915 1920
14. U.E. Studer, H. Danuser, V.W. Merz, J.P. Springer, and E.J. Zingg Experience in 100 patients with an ileal low pressure bladder substitute combined with an afferent tubular isoperistaltic segment J Urol 154 1995 49 56
15. L.H. Sobin, M.K. Gospodarowicz, and C. Wittekind TNM Classification of malignant tumours ed 7 2009 Wiley & Sons New York, NY
16. J. Kononen, L. Bubendorf, and A. Kallioniemi Tissue microarrays for high-throughput molecular profiling of tumor specimens Nat Med 4 1998 844 847 (Pubitemid 28331029)
17. P. Regitnig, W. Schippinger, M. Lindbauer, H. Samonigg, and S.F. Lax Change of HER-2/neu status in a subset of distant metastases from breast carcinomas J Pathol 203 2004 918 926 (Pubitemid 39089280)
18. D.E. Hansel, E. Swain, R. Dreicer, and R.R. Tubbs HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases Am J Clin Pathol 130 2008 274 281
19. R.E. Jimenez, M. Hussain, and F.J. Bianco Jr. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors Clin Cancer Res 7 2001 2440 2447 (Pubitemid 32751647)
20. G. Sauter, J. Lee, J.M. Bartlett, D.J. Slamon, and M.F. Press Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations J Clin Oncol 27 2009 1323 1333
21. H. Yaziji, L.C. Goldstein, and T.S. Barry HER-2 testing in breast cancer using parallel tissue-based methods JAMA 291 2004 1972 1977 (Pubitemid 38544278)
22. W.J. Gullick, S.B. Love, and C. Wright c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes Br J Cancer 63 1991 434 438